journal
https://read.qxmd.com/read/38173393/leveraging-gwas-path-to-prevention
#21
JOURNAL ARTICLE
Stacey J Winham, Mark E Sherman
Developing novel cancer prevention medication strategies is important for reducing mortality. Identification of common genetic variants associated with cancer risk suggests the potential to leverage these discoveries to define causal targets for cancer interception. Although each risk variant confers small increases in risk, researchers propose that blocking those that produce causal carcinogenic effects might have large impacts on cancer prevention. While a promising concept, we describe potential hurdles that may need to be scaled to reach this goal, including: (i) understanding the complexity of risk; (ii) achieving statistical power in studies with binary outcomes (cancer development: yes or no); (iii) characterization of cancer precursors; (iv) heterogeneity of cancer subtypes and the populations in which these diseases occur; (v) impact of static genetic markers across complex events of the life course; (vi) defining gene-gene and gene-environment interactions and (vii) demonstrating functional effects of markers in human populations...
January 4, 2024: Cancer Prevention Research
https://read.qxmd.com/read/38154464/breast-cancer-polygenic-risk-score-influence-on-risk-reducing-endocrine-therapy-use-genetic-risk-estimate-genre-trial-1-year-and-2-year-follow-up
#22
JOURNAL ARTICLE
Daniela L Stan, Julian O Kim, Daniel J Schaid, Erin E Carlson, Christina A Kim, Jason P Sinnwell, Fergus J Couch, Celine M Vachon, Andrew Cooke, Benjamin A Goldenberg, Sandhya Pruthi
Refinement of breast cancer (BC) risk estimates with a polygenic risk score (PRS) may improve uptake of risk-reducing endocrine therapy (ET). A previous clinical trial assessed the influence of adding a PRS to traditional risk estimates on ET use. We stratified participants according to PRS-refined BC risk and evaluated ET use and ET-related quality of life (QOL) at 1-year (previously reported) and 2-year follow-ups. Of 151 participants, 58 (38.4%) initiated ET, and 22 (14.6%) discontinued ET by 2 years; 42 (27...
December 28, 2023: Cancer Prevention Research
https://read.qxmd.com/read/38037384/treatment-of-cervical-precancers-is-the-major-remaining-challenge-in-cervical-screening-research
#23
JOURNAL ARTICLE
Kanan T Desai, Silvia de Sanjosé, Mark Schiffman
Deepening understanding of cervical cancer pathogenesis has yielded one-dose prophylactic human papillomavirus (HPV) vaccines and accurate HPV-based cervical screening tests. Knowing the heterogeneous carcinogenic potential of the individual high-risk HPV types permits prioritization of vaccination and screening strategies. However, "correct" (i.e., safe and effective) treatment of women found to have precancer is still undefined, forcing reliance on one or more rounds of untargeted destructive/excisional treatment...
December 1, 2023: Cancer Prevention Research
https://read.qxmd.com/read/38037383/cancer-prevention-perspective-the-university-of-kansas-cancer-center
#24
REVIEW
Roy A Jensen, Christie A Befort
Despite the incredible progress that has been made against cancer over the last few decades, the demographic trends in the United States predict that we will see significant increases in cancer incidence and mortality by the year 2030. This, coupled with an aging cancer workforce, would suggest that we will have major challenges ahead in dealing with the increasing burden from cancer. Clearly a critical part of our strategy must be to focus on cancer prevention and control (CPC) efforts and not solely rely on treatment to mitigate this concerning trend...
December 1, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37768937/knowledge-mediates-the-effects-of-game-changers-for-cervical-cancer-prevention-gc-ccp-intervention-on-increased-via-screening-advocacy-in-uganda
#25
RANDOMIZED CONTROLLED TRIAL
Glenn J Wagner, Joseph K B Matovu, Margrethe Juncker, Eve Namisango, Jolly Beyeza-Kashesya, Rhoda K Wanyenze
UNLABELLED: Game Changers for Cervical Cancer Prevention (GC-CCP), a group advocacy training intervention, has been shown to increase cervical cancer prevention and screening advocacy. In this secondary analysis, we examined mediators and moderators of this effect. A randomized controlled trial of GC-CCP-a 7-session, peer led intervention designed to empower women to engage in cervical cancer prevention advocacy-was conducted with women who had recently been screened by visual inspection of the cervix with acetic acid for cervical cancer...
December 1, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37976537/comparing-breast-cancer-and-cardiovascular-disease-risk-and-use-of-chemoprevention-and-statins-among-women-with-high-risk-breast-lesions
#26
JOURNAL ARTICLE
Kehinde O Lawal, Luisa Nilan, Jacquelyn Amenta, Julia E McGuinness, Rita Kukafka, Katherine D Crew
UNLABELLED: Breast cancer chemoprevention with selective estrogen receptor modulators (SERM) or aromatase inhibitors (AI) remains underutilized among high-risk women. A potential barrier to chemoprevention is competing comorbidities such as atherosclerotic cardiovascular disease (ASCVD), due to concern for additional medication side effects. We conducted a retrospective cohort study among women with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS), an important target population for chemoprevention...
November 16, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37967575/early-onset-colon-cancer-shows-a-distinct-intestinal-microbiome-and-a-host-microbe-interaction
#27
JOURNAL ARTICLE
Darbaz Adnan, Jonathan Q Trinh, Deepak Sharma, Muhammad Alsayid, Faraz Bishehsari
The incidence rate of colorectal cancer (CRC) in younger adults has been rising in developed countries. This trend may be attributed to environmental exposures as a result of lifestyle changes. Many of the lifestyle factors that promote CRC can also affect the gut microbiome, which may be associated with CRC risks. The role of the microbiome in the ongoing rise of early-onset CRC is unknown. Here, we aimed to investigate age-related differences in the gut microbiome of CRC patients and healthy individuals by examining both the fecal and tumor microbiomes...
November 16, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37956420/high-fat-diet-promotes-acute-promyelocytic-leukemia-through-ppar%C3%AE-enhanced-self-renewal-of-preleukemic-progenitors
#28
JOURNAL ARTICLE
Luca Mazzarella, Paolo Falvo, Marta Adinolfi, Giulia Tini, Elena Gatti, Rossana Piccioni, Emanuele Bonetti, Elena Gavilán, Debora Valli, Alicja Gruszka, Margherita Bodini, Barbara Gallo, Stefania Orecchioni, Giulia de Michele, Enrica Migliaccio, Bruno A Duso, Sophie Roerink, Mike Stratton, Francesco Bertolini, Myriam Alcalay, Gaetano Ivan Dellino, Pier Giuseppe Pelicci
Risk and outcome of Acute Promyelocytic Leukemia (APL) are particularly worsened in obese-overweight individuals, but the underlying molecular mechanism is unknown. In established mouse APL models (Ctsg-PML::RARA), we confirmed that obesity induced by High-Fat Diet (HFD) enhances leukemogenesis by increasing penetrance and shortening latency, providing an ideal model to investigate obesity-induced molecular events in the preleukemic phase. Surprisingly, despite increasing DNA damage in hematopoietic stem cells (HSCs), HFD only minimally increased mutational load, with no relevant impact on known cancer-driving genes ...
November 13, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37940143/examining-the-association-between-abstinence-from-smoking-and-healthcare-costs-among-patients-with-cancer
#29
JOURNAL ARTICLE
George Kypriotakis, Seokhun Kim, Maher Karam-Hage, Jason D Robinson, Jennifer A Minnix, Janice A Blalock, Yong Cui, Diane Beneventi, Bumyang Kim, I-Wen Pan, Ya-Chen Tina Shih, Paul M Cinciripini
Continuous tobacco use in cancer patients is linked to substantial healthcare costs due to increased risks and complications, whereas quitting smoking leads to improved treatment outcomes and cost reductions. Addressing the need for empirical evidence on the economic impact of smoking cessation, this study examined the association between smoking cessation and healthcare cost utilization among a sample of 930 cancer patients treated at The University of Texas MD Anderson Cancer Center's Tobacco Research and Treatment Program (TRTP)...
November 8, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37913800/experiences-of-family-communication-and-cascade-genetic-testing-for-hereditary-cancer-in-medically-underserved-populations-a-qualitative-study
#30
JOURNAL ARTICLE
Erica M Bednar, J Alejandro Rauh-Hain, Jose J Garcia, Norma de Aguinaga, Mary Anne Powell, Sylvia L Peral, Roni Nitecki, Kirsten Jorgensen, Natasha L Rudy, Karen H Lu, Charles A Leath, Isabel C Scarinci
We sought to explore the intrafamilial communication and cascade genetic testing (CGT) experiences of patients with hereditary cancer from diverse, medically underserved populations and their relatives. Participants included patients receiving oncology care at an urban, safety-net hospital in Texas or comprehensive cancer center in Alabama and their first-degree relatives. In-depth semi-structured qualitative interviews were completed wherein patients shared their experiences with genetic counseling (GC), genetic testing (GT), and communicating their results to relatives...
November 2, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37908146/rutgers-cancer-institute-of-new-jersey-s-community-outreach-and-engagement-approach-to-cancer-prevention
#31
JOURNAL ARTICLE
Anita Y Kinney, Antoinette M Stroup, Sarah Scharf, Steven K Libutti
Rutgers Cancer Institute of New Jersey (New Brunswick, NJ) is committed to providing cancer prevention education, outreach, and clinical services in our catchment area (CA). Our approach to cancer prevention includes ongoing surveillance to better understand the CA cancer burden and opportunities for intervention, leveraging community partnerships, and vigorously engaging diverse communities to understand and address their needs. This approach considers individual, sociocultural, environmental, biologic, system, and policy-level factors with an equity lens...
November 1, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37857481/preventive-treatment-with-pd-1-antibody-increases-tissue-resident-memory-t-cells-infiltration-and-delays-esophageal-carcinogenesis
#32
JOURNAL ARTICLE
Zeru Xiao, Rui Yan, Heshu Liu, Xuying Huang, Ziwei Liang, Guangyu An, Yang Ge
Numerous studies and clinical trials have shown that immune checkpoint inhibitors can effectively prevent tumor growth and metastasis in esophageal squamous cell carcinoma (ESCC) patients. In this study, we aimed to evaluate the anti-tumor effects of PD-1 antibody preventive treatment in patients with early stages ESCC as well as patients with high-grade intraepithelial neoplasia (HGIN). We first established an ESCC model using C57BL/6J mice treated with the chemical carcinogen 4- NQO and observed esophageal lesions at different time points...
October 17, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37788346/clinical-performance-of-hrhpv-primary-screening-using-vaginal-versus-cervical-samples-to-detect-high-grade-intraepithelial-lesions
#33
JOURNAL ARTICLE
Jonathan King, Yvonne N Flores, Joacim Meneses-León, Sonia Hernández-Salazar, Karina Robles-Rivera, Berenice Rivera-Paredez, Leith León-Maldonado, Rubí Hernández-López, Leticia Torres-Ibarra, Eduardo Lazcano-Ponce, Jorge Salmerón
High-risk human papillomavirus (hrHPV) testing is now the most recommended primary method for cervical cancer screening worldwide. Clinician-collected cervical sampling continues to be the main sampling method, but hrHPV vaginal self-sampling is an appealing alternative because of its greater acceptability and potentially higher cost-effectiveness. This study aimed to determine if hrHPV vaginal self-sampling is comparable to clinician-collected cervical sampling for detecting histologically confirmed high-grade cervical intraepithelial neoplasia (CIN2/3) as part of a cervical cancer screening program in Mexico...
October 3, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37779459/opportunities-to-improve-hpv-vaccination-among-pediatric-adolescent-and-young-adult-cancer-survivors-by-engaging-both-oncology-and-primary-care-teams
#34
EDITORIAL
Melinda Butsch Kovacic, Alique Topalian, Melissa Erickson
The incidence of second primary cancers is rising particularly among pediatric, adolescent, and young adult (PAYA) cancer survivors. While human papillomavirus (HPV)-associated cancers can be prevented by vaccination, their uptake is lower and delayed in this group. Because a recommendation from a health care provider is the strongest predictor of HPV vaccination, there are great opportunities for PAYA cancer care providers to positively impact HPV vaccination rates. Prioritizing PAYA cancer care provider education as well as improving the education of and coordination with primary care providers are viewed as opportunities to encourage HPV vaccine uptake and prevent future cancers...
October 2, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37779458/alvin-j-siteman-cancer-center-cancer-prevention-perspective
#35
JOURNAL ARTICLE
Graham A Colditz, Bettina F Drake, Timothy J Eberlein
We summarize Siteman Cancer Center catchment that covers 82 counties in southern Illinois and eastern Missouri. We note both the high poverty and cancer rates in many rural counties. Siteman Community Outreach and Engagement has developed a number of strategies to move towards achieving health equity. These include NCI-funded research projects in rural clinics and outreach to improve access to cancer prevention services. To increase capacity for community-engaged research, we have developed and refined a Community Research Fellows Training Program...
October 2, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37258419/examining-the-barriers-and-opportunities-for-human-papillomavirus-vaccine-delivery-in-cancer-care-settings-a-mixed-methods-study
#36
JOURNAL ARTICLE
Melany A Garcia, Nicolas F Schlecht, Denise A Rokitka, Kristopher M Attwood, Elisa M Rodriguez
UNLABELLED: Although pediatric, adolescent, and young adult (PAYA) cancer survivors are at increased risks for secondary cancers, their HPV vaccine uptake rates are poor. Therefore, we conducted a mixed-methods study to identify the barriers and opportunities for HPV vaccine delivery among PAYA cancer care providers. We distributed a semistructured questionnaire to a professional organization comprised of PAYA oncology and hematology healthcare providers between April and July 2022. Questionnaire measures included demographic and practice characteristics, HPV vaccine knowledge, willingness, barriers, opportunities, and roles for HPV vaccine delivery...
October 2, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37756582/polymorphisms-in-cyclooxygenase-lipoxygenase-and-tp53-genes-predict-colorectal-polyp-risk-reduction-by-aspirin-in-the-seafood-polyp-prevention-trial
#37
JOURNAL ARTICLE
John R Davies, Tracey Mell, Harriett Fuller, Mark Harland, Rasha Nm Saleh, Amanda D Race, Colin J Rees, Louise C Brown, Paul M Loadman, Amy Downing, Anne Marie Minihane, Elizabeth A Williams, Mark A Hull
Aspirin and eicosapentaenoic acid (EPA) reduce colorectal adenomatous polyp risk and affect synthesis of oxylipins including prostaglandin E2. We investigated whether 35 single nucleotide polymorphisms (SNPs) in oxylipin metabolism genes such as cyclooxygenase [PTGS] and lipoxygenase [ALOX], as well as 7 SNPs already associated with colorectal cancer (CRC) risk reduction by aspirin (eg. TP53; rs104522), modified the effects of aspirin and EPA on colorectal polyp recurrence in the randomised 2x2 factorial seAFOod trial...
September 26, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37756580/dynamic-risk-prediction-of-treatment-discontinuation-using-patient-reported-outcomes-data-in-the-phase-iii-nsabp-b-35-trial
#38
JOURNAL ARTICLE
Vinicius F Calsavara, Norah L Henry, Ron D Hays, Sungjin Kim, Michael Luu, Márcio A Diniz, Gillian Gresham, Reena S Cecchini, Greg Yothers, Patricia A Ganz, André Rogatko, Mourad Tighiouart
Predicting an individual's risk of treatment discontinuation is critical for the implementation of precision chemoprevention. We developed partly conditional survival models to predict discontinuation of tamoxifen or anastrozole using patient-reported outcome (PRO) data from postmenopausal women with ductal carcinoma in situ (DCIS) enrolled in the NSABP B-35 clinical trial. In a secondary analysis of the NSABP B-35 clinical trial PRO data, we proposed two models for treatment discontinuation within each treatment arm (anastrozole or tamoxifen treated patients) using partly conditional Cox-type models with time-dependent covariates...
September 26, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37728516/methylated-dna-markers-for-sporadic-colorectal-and-endometrial-cancer-are-strongly-associated-with-lynch-syndrome-cancers
#39
JOURNAL ARTICLE
Rachel M Bramblet, Jamie N Bakkum-Gamez, Seth W Slettedahl, Patrick H Foote, William R Taylor, Calise K Berger, Brianna J Gysbers, Jacquelyn Arndt, Longwen Chen, Karen A Doering, Kelli N Burger, Douglas W Mahoney, Mark E Sherman, John B Kisiel, N Jewel Samadder
UNLABELLED: Lynch syndrome (LS) markedly increases risks of colorectal and endometrial cancers. Early detection biomarkers for LS cancers could reduce the needs for invasive screening and surgical prophylaxis.To validate a panel of methylated DNA markers (MDM) previously identified in sporadic colorectal cancer and endometrial cancer for discrimination of these cancers in LS.In a case-control design, previously identified MDMs for the detection of colorectal cancer and endometrial cancer were assayed by qMSP on tissue-extracted DNA...
September 20, 2023: Cancer Prevention Research
https://read.qxmd.com/read/37732897/aacr-cancer-centers-alliance-fostering-collaboration-and-innovation-to-advance-lifesaving-scientific-discoveries-for-patients
#40
JOURNAL ARTICLE
Carlos L Arteaga, John L Cleveland, Margaret Foti, Ruben A Mesa, Louis M Weiner, Cheryl L Willman, David A Tuveson
Basic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers Alliance will accelerate the pace of discovery by providing an ongoing mechanism for transferring new knowledge, sharing resources, developing national demonstration projects, and driving innovation that impacts cancer science, cancer care delivery, and science and health policy...
September 13, 2023: Cancer Prevention Research
journal
journal
42075
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.